No question is so difficult to answer as that to which the answer is obvious George Bernard Shaw
Personalized medicine is an increasingly popular phrase in clinical practice, with both patients and physicians desirous of informed and individualized decision-making. While a popular phrase, many clinicians seem to still have a futuristic vision of what personalized medicine means, evoking words that end in omic and inevitably machine learning and artificial intelligence while ignoring growing data supporting imaging-guided medical therapy decision-making. Over the last 50 years, the pioneers of modern preventive cardiology identified clinical risk factors and clearly demonstrated a population-based relationship to atherosclerotic cardiovascular disease (ASCVD) events. While powerful at predicting risk of events at the population level, 1 the relationship between traditional risk factors and downstream events is only modest on an individual patient level.
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Most practice guidelines recommend using risk estimate tools for risk stratification of the patient for ASCVD. It is most commonly understood that the risk calculated by these tools is the individual patient's exact risk for developing an ASCVD event in the defined period of time. While 'low-risk' patients do not receive any anti-atherosclerotic therapy, some 'intermediate-risk' and all 'high-risk' patients do. This pattern of practice is the perfect example of applying population-derived data to individual patients.
The risk estimate scores do not give us personalized risks; instead they tell us that the patient belongs to a certain population and that a certain percentage of that population in the next specified amount of time will develop events. The therapeutic decision for the patientoften lifelong therapy-is made based on the risk of the population they belong to, not their personalized risk. This application of population medicine to individual patients leads to undertreatment of 10-15% of patients in the low-risk category and sometimes overtreatment of patients in the high-risk category. In the intermediate-risk group, clinical decision-making approaches tossing a coin regarding certainty.
What MESA and other similar outcome studies have demonstrated clearly over the last two decades is that with presence or absence of each clinical risk factor or any combination of risk factors, there are patients who develop and those who do not develop subclinical atherosclerosis. Importantly, across all populations studied, subclinical atherosclerosis provides more robust risk discrimination than traditional cardiovascular risk factors. [4] [5] [6] [7] With growing data from large registries such as MESA and other large multicentre collaborations highlighting the warranty period of a negative calcium score out to 15 years in low-to intermediate-risk patients, 8 there is increasing use of a negative calcium score to serve as a clinical arbiter often driven by the reticence of patients to commit to long-term medical therapy. Unfortunately, perhaps owing to concern regarding overtreatment, a much more conservative approach has been taken with patients with moderate coronary calcification. This approach continues despite growing intermediate and longer term data highlighting the hazard associated with the presence of coronary atherosclerosis. In this issue of the journal, Budoff and colleagues 8 provide important data adding to the argument that this conservative approach to integration of a coronary artery calcium score (CACS) comes with significant patient risk. In a 10-year outcome study of MESA, the investigators showed that CAC is strongly associated with major adverse cardiovascular events, inclusive of stroke, regardless of sex, race/ethnicity, or age group. In addition, the data presented suggest that a CACS >100, lower than the currently used 300, signifies at least a 7.5% 10-year risk of ASCVD. Importantly, at this risk threshold, the guidelines would support considering initiating statin therapy, suggesting that the current threshold is missing a significant number of patients at risk. Importantly, these findings held true across multiple sociodemographic groups. The findings of increased risk for those with an elevated CACS was found while also describing a significant reduction amongst those without calcification (<6% 10-year event rate) in a fashion that is consistent with a growing amount of long-term data. Finally, it is worth noting that this robust risk stratification is maintained both in patients on statins and in those that were statin naïve.
With the data presented in the study of Budoff et al., the case to ignore a CACS >100 is becoming increasingly tenuous. The decision to ignore such findings is commonly justified by 'normal'-population-defined-LDL values or minimal clinical risk factors despite patient-specific evidence of moderate coronary atherosclerosis. Perhaps it is time we refine our definition of what a normal LDL level is. Is it a normal LDL if the patient has moderate, premature, or coronary artery disease greater than most patients of similar age and sex? Is it time for a conceptual change and to consider a new definition of a 'normal LDL? Perhaps, a normal LDL is the level that does not permit premature or progressive atherosclerosis, and could be different for different individuals. While the evidence is modest in an asymptomatic patient, we have growing data from coronary computed tomography
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Take home figure (A) Population risk vs. individual risk: the risk estimate scores do not give us personalized risks; instead they tell us that the patient belongs to a certain population and a certain percentage of that population in the next specified amount of time will develop events. Using these tools, we can correctly identify the risk for a population and conclude that a population with risk factor(s) has a higher chance of ASCVD events as compared with a population without risk factors. However, we cannot estimate the risk of ASCVD for the individual patients within each group. (B) Clinical scenarios: two cases illustrating that risk estimate tools cannot estimate personalized risks accurately. Case 1 demonstrates a 'low-risk individual' with no identifiable risk factor and 'normal' lipid profile, that has seven segments of coronary artery disease, including two intermediate lesions (50-69%) at the proximal LAD and proximal LCx. Case 2 demonstrates a patient with hypertension, possible familial hypercholesterolaemia, and a very abnormal lipid profile, with completely normal coronary arteries, with no evidence of coronary atherosclerosis. (C) Current vs. future risk stratification models: currently, as recommended by practice guidelines, we risk-stratify patients with identification and treatment of the traditional risk factors with the aim of preventing development of clinical ASCVD and subsequent ASCVD events. Even though formation of clinical ASCVD is a basis for ASCVD events (green check mark), the relationship between risk factors and clinical ASCVD is far from perfect (red question mark), as there are many patients with risk factors that do not develop ASCVD and many patients without identifiable risk factors that do develop ASCVD. The future model is based on the data from MESA and other large multicentre studies that have clearly demonstrated superiority of subclinical atherosclerosis compared with risk factors in risk prediction; we proposed that the model in the future should include routine screening for subclinical atherosclerosis as it is clearly a first step towards personalized medicine; leading to better identification of patients-not populations-at risk and more targeted therapy. With identification of subclinical atherosclerosis, aggressive anti-atherosclerotic therapy could prevent plaque progression and stabilize plaque morphology, preventing clinical ASCVD and ASCVD events from formation, in most cases. angiography, invasive angiography, and intravascular ultrasound that treating atherosclerosis when identified is effective in preventing plaque progression, changing plaque morphology to a more stable form, and helps to reduce events significantly. 9, 10 We aggressively treat all individuals with lipid-lowering therapy after the first ASCVD events, independent of the risk factor profile (secondary prevention). Is it not the time to take the same approach upon detection of significant subclinical atherosclerosis to prevent that first event?
For calcium scoring to be considered as the early step towards personalized medicine, it needs to be interpreted in a personalized fashion with the goal of preventing an ASCVD event not within 10 years but ideally over the patient's lifetime. A calcium score <100 should be interpreted differently in a young patient with no identifiable risk factor as compared with an older patient with or without risk factors. In both cases, a calcium score <100 confirms the presence of atherosclerosis and risk below 7.5% in the next 10 years. However, for a younger patient, preventing ASCVD events in the next 10 years may not be the main issue to be addressed. Therefore, the same calcium score in two different individuals can lead to different personalized therapeutic decision-making that is customized to that individual's care.
With concerns around radiation dose fading with newer dose reduction strategies and cost seemingly no longer an issue in most healthcare environments, we are left with a simple question. What answer needs to be shared for more robust clinical adoption? The investigators in the field of coronary calcification scoring and subclinical atherosclerosis have consistently provided the same clear answer and yet it is seemingly not the answer the field of cardiovascular medicine wants to hear. Why in an era of calls for individualized care are we willing to ignore such a powerful and yet simple imaging biomarker? Is it not yet the time to move from risk assessment to direct visualization of the disease? Is it not yet the time to start treating the disease as opposed to the risk for the disease?
